Galapagos, BASF extend research collaborations

By E. Janene Geiss

Philadelphia, Feb. 2 - Galapagos NV announced Thursday that it has extended three research collaborations into 2006 with BASF AG.

These extensions will further progress discovery research services for BASF programs successfully undertaken by Galapagos' service division BioFocus in 2005, according to a company news release.

Across the various programs, BioFocus said it will offer biology, synthetic and computational chemistry services in addition to access to its biologically targeted SoftFocus Kinase and GPCR compound libraries against further BASF targets.

Under terms of the extension agreements, BASF will pay compound supply and access fees and will fund research. Total contract value of the extensions will exceed €700,000, officials said.

"We are delighted that BASF has chosen to extend these collaborations with BioFocus," said Onno van de Stolpe, chief executive officer of Galapagos, in the release. "We believe that our expertise in the area of kinase and GPCR biology and chemistry, together with our proprietary compound libraries, place BioFocus in an excellent position to progress BASF's discovery programs rapidly."

Galapagos is a Mechelen, Belgium, genomics-based pharmaceutical company that has drug discovery programs based on proprietary, novel targets in the bone and joint diseases - osteoarthritis, osteoporosis and rheumatoid arthritis.

BASF is a chemical manufacturing company in Ludwigshafen, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.